Oppenheimer Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $51
Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. EWTX | 0.00 |
Oppenheimer analyst Mazahir Alimohamed initiates coverage on Edgewise Therapeutics (NASDAQ:
EWTX) with a Outperform rating and announces Price Target of $51.
